BBNX CEO Sean Saint gets major equity awards and small tax-related share sale

Rhea-AI Filing Summary

Beta Bionics, Inc. President & CEO Sean Saint reported a mix of equity awards and a small tax-related share sale. On February 27, 2026, he acquired 343,269 shares of common stock as a restricted stock unit award under the 2025 Equity Incentive Plan and received an employee stock option for 184,837 shares, which vests in 36 equal monthly installments starting March 1, 2026. On March 2, 2026, he sold 3,384 shares of common stock in an open-market transaction at a weighted average price of $12.3616, solely to cover tax withholding obligations from restricted stock unit vesting, and held 437,809 common shares directly afterward.

Insider Trade Summary

Net Seller: 3,384 shares ($41,832)

Net Sell 3 txns

Insider Saint Sean

Role President & CEO

Sold 3,384 shs ($42K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,384	$12.3616	$42K
Grant/Award	Employee Stock Option (right to buy)	184,837	$0.00	--
Grant/Award	Common Stock	343,269	$0.00	--

Holdings After Transaction: Common Stock — 437,809 shares (Direct); Employee Stock Option (right to buy) — 184,837 shares (Direct)

Footnotes (1)

1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. The weighted average sale price for the transaction reported was $12.3616 and the range of prices were between $12.20 and $12.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saint Sean

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A		343,269(1)	A	$0	441,193	D
Common Stock	03/02/2026		S(2)		3,384	D	$12.3616(3)	437,809	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$12.63	02/27/2026		A		184,837		(4)	02/26/2036	Common Stock	184,837	$0	184,837	D

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

2. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

3. The weighted average sale price for the transaction reported was $12.3616 and the range of prices were between $12.20 and $12.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

4. The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.

	/s/ Stephen Feider, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did BBNX President & CEO Sean Saint report?

Sean Saint reported equity grants and a small tax-related sale. He received 343,269 shares via restricted stock units and an option for 184,837 shares, then sold 3,384 shares to cover tax withholding from vesting.

How many Beta Bionics (BBNX) shares did Sean Saint sell and at what price?

Sean Saint sold 3,384 shares of Beta Bionics common stock. The weighted average sale price was $12.3616 per share, within a range of $12.20 to $12.55, and the sale was to cover tax withholding obligations on vesting restricted stock units.

Were Sean Saint’s BBNX share sales discretionary or for taxes?

The reported sale was for taxes, not discretionary portfolio changes. The 3,384 shares were sold specifically to cover tax withholding obligations tied to the vesting of restricted stock units, according to the transaction footnote.

What restricted stock unit award did Sean Saint receive from Beta Bionics (BBNX)?

Sean Saint received a restricted stock unit award representing 343,269 shares of common stock. The award was granted under Beta Bionics’ 2025 Equity Incentive Plan, increasing his direct equity-based compensation in the company alongside existing holdings.

What are the terms of Sean Saint’s new employee stock option at BBNX?

Sean Saint was granted an employee stock option covering 184,837 shares. The option vests in 36 equal monthly installments beginning March 1, 2026, meaning the right to exercise the option increases gradually over a three-year period.

How many Beta Bionics (BBNX) shares did Sean Saint own after these transactions?

After the reported transactions, Sean Saint directly held 437,809 shares of Beta Bionics common stock. This figure reflects his position following the 3,384-share tax-related sale completed on March 2, 2026.